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Introduction: Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the
population with both quality of life and economic implications. To date, the pain associated with migraine and
tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition,
the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for
both patients and physicians.
Case presentations: Four women with long histories of migraine or frequent tension-type headache that meet the
International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were
given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from
lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients,
both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18
months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of
migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a
temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines
to date for 1 month. Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal
anti-inflammatory drugs and paracetamol.
Conclusions: This case series is the first to provide evidence of the efficacy of autologous StroMed and
stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by
stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment
that may help address the symptoms of the disease. Given what is known about the components of the stromal
vascular fraction and how they act, the information presented in this case series may also further our knowledge of the
etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely
effective and has been life changing for these patients.
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The therapeutic rationale for use of stromal vascular
fraction (SVF) cells and the high content of native multi-
potent adipose-derived stem/stromal cells (ASCs) within
the SVF has gained recent substantial clinical interest.
SVF typically has been reported to contain a heteroge-
neous population of cells including preadipocytes, ASCs,
endothelial progenitor cells (EPCs), T-regulatory cells
and M2 macrophages [1]. The method of harvesting, the
site and separation of these cells may result in differing* Correspondence: rbright@macquariestemcells.com
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unless otherwise stated.proportions of these populations. Although, a large body
of work has focused on cultured mesenchymal stem cells
(MSCs) or ASCs with their effect on a multitude of dis-
eases, SVF is an easily obtainable cell population which
does not require culture and can be used in an autologous
manner with little risk of disease transfer or the complica-
tions arising from cultured ASCs for clinical use.
Cellular populations of SVF such as ASCs have been
shown to have significant immunomodulatory capabilities,
capable of homing to sites of inflammation or hypoxia
and promote recovery in both animal and human models
[1]. Furthermore, intravenous (IV) injection of SVF has
been shown to be safe without significant adverse effectstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bright et al. Journal of Medical Case Reports 2014, 8:237 Page 2 of 5
http://www.jmedicalcasereports.com/content/8/1/237[2]. SVF from adipose tissue has also been used in clinical
applications with improvements demonstrated in fat trans-
fer, osteoarthritis and Crohn’s disease.
Several methods for separation of SVF from lipoaspi-
rate are available and include collagenase and ultrasonic
cavitation; the SVF product obtained by ultrasonic cavi-
tation has been termed “StroMed”. Although, SVF has
not previously been used in the treatment of migraines
in animal or human models, we noted that some pa-
tients that were treated with SVF for osteoarthritis re-
ported a reduction in migraine frequency and severity. A
small case series was performed on patients who had
failed all other migraine treatments. Treatment of au-
tologous SVF by a medical practitioner is a procedure
permitted by the Therapeutic Goods Administration of
Australia (Excluded Goods Order−2011). Informed writ-
ten consent was obtained from each patient and the
study protocol conformed to the principles of the 1975
Declaration of Helsinki.
Migraine is a common, episodic neurological disorder.
It manifests as episodes of recurrent severe headaches,
typically unilateral and throbbing, which may be associ-
ated with nausea, vomiting, photophobia or phonopho-
bia. Approximately one-third of patients with migraine
also experience ‘aura’ – transient neurological symptoms
which are most frequently visual, but may involve speech
and/or other senses [3]. Both migraine with and without
aura are three times more common in females than
males [4]. Tension-type headache (TTH) differs slightly
in that it is defined clinically as a mild or moderate bilat-
eral headache, with a pressing or tightening quality. These
headaches can last from 30 minutes to 7 days and are asso-
ciated with phonophobia and photophobia. Both migraine
and TTH are significant public health problems, impacting
greatly on both individuals and society. Migraine is cur-
rently treated both acutely and prophylactically utilizing:
non-steroidal anti-inflammatory drugs (NSAIDs), triptans,
anti-epileptics, beta-blockers, and Ca2+ channel blockers
[4]. Unfortunately, due to the heterogeneity of these head-
ache syndromes–particularly migraine–the current treat-
ments vary greatly in their efficacy [3].
While it is generally agreed that migraine is a hetero-
geneous neurological disorder, the detail of its pathophysi-
ology is as yet unconfirmed with inheritance thought to
be as high as 50%. A migraine attack can take place over
hours to days and include four overlapping phases: pre-
monitory, aura, headache and postdrome, with the mecha-
nisms leading to an attack largely unknown. The aura and
headache phase generally overlap with a large body of in-
direct evidence suggesting the development of headache
relies on the activation and sensitization (A/S) of neurons
in the trigeminal nerve. A/S of the trigeminal nociceptors,
particularly those that innervate the meninges and large
cranial blood vessels, may further propel A/S of second-and third-order central trigeminovascular neurons. As
these neurons project to nuclei in the brain stem and fore-
brain, including the ‘pain matrix’, they are considered to
be the underlying cause of both migraine pain and other
migrainous symptoms, including loss of appetite and
sleepiness [3]. The pain matrix consists of all the parts of
the brain whose activity fluctuates when an individual is
experiencing pain.
The origin of the damaging stimuli by which the men-
ingeal receptors become activated is unclear with two
central hypotheses put forward: cortical spreading de-
pression (CSD) and neurogenic inflammation. There is
increasing evidence that the brief neuronal excitation
followed by prolonged inhibition of activity that spreads
across the cortex, referred to as CSD, is implicated in the
pathophysiology of migraine [5]. The inhibition of neuronal
activity appears to be correlated with localized changes in
blood flow in patients, and sustained activation of the men-
ingeal nociceptors and central trigeminovascular neurons
to occur by the extracellular release and diffusion of mole-
cules such as potassium and hydrogen ions, and glutamate
in the cortex. In addition, or alternatively, CSD may also
trigger neurogenic inflammation.
The neurogenic inflammation hypothesis proposes
that the release of inflammatory neuropeptides such as
calcitonin gene-related peptide, substance P and neuro-
kinin A from trigeminal sensory afferents leads to vaso-
dilatation, mast cell degranulation and ensuing release of
cytokines, platelet aggregation and extravasation of plasma
proteins. Of interest, most C-type and slow A-delta-
type rat dural afferents are activated and sensitized by
an inflammatory soup (IF) of potassium, prostaglan-
dins, 5-hydroxtryptamine, bradykinin and histamine
[6], supporting the role of inflammation in migraine
pathophysiology. In addition, these dural fibers are mechan-
osensitive and IF enhances their mechanosensitivity–
perhaps explaining why migraine headaches are throbbing,
and exacerbated by actions that increase intracranial pres-
sure [7]. Clinical support for inflammation’s role comes
from the efficacy of NSAIDs.
Recent theories surrounding TTH also implicate neur-
onal plasticity in its pathogenesis. As reviewed in Fumal
and Schoenen [8], increased nociceptive input from peri-
cranial myofascial tissues is thought to be important for in-
frequent TTH and leads to sensitization of nociceptive
second-order neurons in the C2 and C3 dorsal horns and
trigeminal nucleus. Whereas dysfunctional nociception in
the central nervous system is proposed to be predomin-
antly related to chronic TTH, invariably these mechanisms
appear to be intermingled in the pathogenesis of TTH.
Although there exists sufficient evidence to reject the
original vascular theory of migraine of dilation of extra-
cranial arteries, vascular dysfunction is still thought to
be implicated in migraine. Numerous studies have indicated
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ferences in endothelial function in migraineurs remain con-
troversial. EPCs normally act as an endogenous repair
mechanism, counteracting endothelial cell injury and re-
placing dysfunctional epithelium to maintain endothelial
integrity after damage has occurred [9]. Reduced number
and function of EPCs have been reported in migrai-
neurs, although this is debatable. The decreased numbers
could indicate a role for the vascular system in migraine
pathophysiology.
Case presentations
Patients’ adipose tissue was harvested from subcutaneous
locations and they were given 15 to 30mg morphine, 1 to
2mg Ativan® (lorazepam), 10mg Maxolon® (metoclopra-
mide), 50 to 100mg pethidine and 4mg dexamethasone.
The area was cleaned with 0.5% 6-chlorhexidine solution
and an incision made to inject the tumescent fluid by a
16-gauge cannula, which is made up of 800mg lignocaine,
1mg adrenaline and 8.4g sodium bicarbonate per liter.
The adipose tissue was removed by liposuction using
3mm cannula and collected in a sterile container with a
washing solution. This solution was normal 0.9% saline
with 8.4g sodium bicarbonate.
The lipoaspirate was digested with collagenase or by fol-
lowing Cell-Innovations (Australia) standard ultrasonic
cavitation proprietary protocol under sterile conditions to
obtain StroMed. Enzymatic digestion was performed add-
ing 0.05% collagenase with adipose tissue over a period of
45 to 60 minutes. Samples were then centrifuged, and
washed three times before being filtered through a 100um
filter (Merck Millipore, MA, USA). The supernatant was
removed and the pellet resuspended in phosphate buffered
saline or 0.9% saline. A sample was then taken of the SVF
yield and the cells counted using a hemocytometer or the
Muse Cell Analyzer (Merck Millipore, MA, USA) with a
Count and Viability dye (Merck Millipore, MA, USA).
The total cell number was then determined.
Plasma rich in growth factors (PRGF) was prepared by
centrifugation of 2 × 10mL of blood with acid-citrate-
dextrose formula A (450g × 10 minutes). The plasma was
removed and the platelets further concentrated by centri-
fugation at 2000g for 10 minutes. The platelet-poor
plasma was removed and the platelets resuspended in
1.5mL platelet-rich plasma (PRP). The PRP was clotted
with the addition of 150uL of calcium gluconate (10%;
Regen Lab, Lausanne, Switzerland) and after 30 minutes
the PRGF was removed.
Cells were administered IV by dilution in a 1L saline
bag and given intravenously over 1 hour.
Case 1
Case 1 is a 40-year-old Arab woman who is a cigarette
smoker with a lifelong history of chronic migraine andTTH, satisfying the International Classification of Head-
ache Disorders-2 (ICHD-2) criteria. She typically experi-
enced two migraines per day with classic aura, as well as
frequent episodic TTH. She was given a single IV dose of
StroMed (245 million) with PRGF added. At 3 days post-
treatment she noted improvement in her migraine symp-
toms, and had ceased medication for her migraines at 1
month post-treatment. After 3 months post-treatment,
she had experienced only one TTH. At 18 months post-
treatment she experiences only occasional, minor head-
aches that are quickly resolved and do not keep her
bedridden.
Case 2
Case 2 is a 36-year-old Arab woman who is a cigarette
smoker with a long history of migraine, satisfying the
ICHD-2 criteria for chronic migraine. She typically expe-
rienced more than 20 days of migraine per month, and
occasionally required home visits from a doctor for par-
enteral analgesia. She was given a single IV dose of
StroMed (41 million cells) and reported not experiencing
any migraines after 1 month post-treatment. At 12 months
post-treatment, she stated she had only experienced two
strong headaches, which were managed with paracetamol
and no migraines.
Case 3
Case 3 is a 43-year-old Slavic woman who is a non-cigarette
smoker with a long history of migraines and headaches,
satisfying the ICHD-2 criteria for chronic migraine. She
experienced more than 20 days per month of migraine,
and was using a combination of transdermal morphine
patches, oxycodone hydrochloride, and up to eight tab-
lets a day of Panadeine Forte® (co-codamol; 30mg codeine
phosphate, 500mg paracetamol) to control her symptoms.
She was given a single IV dose of autologous adipose
tissue-derived SVF (495 million cells), digested by collage-
nase. After 3 days post-treatment, she noticed a reduction
in her migraine symptoms and ceased using transdermal
morphine; over the next 5 months she was able to control
her symptoms with ibuprofen and paracetamol. After 5
months, minor headaches returned and she was re-treated
at 7 months with a further IV dose of autologous adipose
tissue-derived SVF (638 million cells) with PRGF. She
noticed immediate improvements in her symptoms.
After a period of 18 months she had only experienced
seven migraines.
Case 4
Case 4 is a 44-year-old Asian woman who is a cigarette
smoker satisfying the ICHD-2 criteria for chronic mi-
graine, with a long history of migraines and headaches.
She typically had more than 20 days per month of head-
aches without aura. She experienced mixed tension and
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Forte® (co-codamol; 30mg codeine phosphate, 500mg
paracetamol) per day for headache-associated pain. She
was given a single IV dose of autologous adipose tissue-
derived SVF (546 million cells) by enzymatic extraction
with added PRGF. In the first month post-administration,
she only experienced one headache; it lasted for half an
hour and responded to paracetamol. At 1 month, she ex-
perienced a relapse of her migraine symptoms. She had a
repeat treatment after 18 months and has been free of mi-
graines for at least 1 month afterwards.
Conclusions
This case series provides an important novel direction
in which StroMed or autologous SVF may be used in
treatment of a disease. Given the very heterogeneous
nature of headaches and the various proposed patho-
geneses, all of which may be true, for the different
headaches, we can postulate that there are a number
of ways in which the characteristics of MSCs and
other cellular components of SVF are able to modu-
late the frequency, duration and severity of migraine
and TTH including cell depletion, immunomodulatory
effects and inflammatory pathways. The mechanism
(or mechanisms) of action of SVF when unraveled
may help to shed further light on the pathophysiology
of migraine and TTH.
The inflammatory pathways described in the pathogenesis
of migraine may be addressed by many of the SVF constitu-
ents including M2 macrophages and ASCs. M2 macro-
phages are reported to have potent anti-inflammatory and
immunoregulatory abilities, in particular, the production
of key anti-inflammatory cytokines such as IL-10 and
lipid mediators such as lipoxins. The inhibition of proin-
flammatory molecules by MSCs have also been well
documented in number of diseases including acute lung
injuries, myocardial infarction and cerebral ischemia [10].
A multitude of immunomodulatory effects of MSCs and
ASCs have similarly been demonstrated in the literature
by the regulation of indoleamine 2,3-dioxygenase, trans-
forming growth factor -β1, human leukocyte antigen-G,
prostaglandin E2 and tumor necrosis factor (TNF)-α-in-
duced protein 6 [11]. Indeed MSCs have had a demon-
strated neuroprotective effect on dopaminergic neurons,
which may be hypersensitive in migraine, by a reduction
in nitric oxide and TNF-α and messenger ribonucleic acid
(RNA) expression of lipopolysaccharide-induced micro-
glial activation, TNF-α and inducible nitric oxide synthase
[12]. In general, it may be that the anti-inflammatory and
immunoregulatory properties of the SVF are working to
‘mop up’ the IF that activates and sensitizes dural nocicep-
tive neurons.
Although, as the pain of migraine does not eventuate
and is long term this could suggest that the action ofstromal cells are sufficient to correct deficiencies that
predispose to migraine rather than merely being anti-
inflammatory for the neurogenic inflammation. It could
be presumed that the therapeutic efficacy of infused SVF
relies on either or both the beneficial effects of locally
engrafted SVF cells or systemic effects from secreted
paracrine factors that diffuse into target tissues. The ex-
travasations of systemically infused SVF and engraftment
may also have occurred where they could exhibit both
local trophic or paracrine activity in cell depleted areas.
SVF is also known to contain a high number of EPCs,
in particular StroMed (unpublished data), which are re-
duced in both number and function in migraineurs suf-
ferers. One proposed mechanism of recurrent migraine
attacks is inflammation, hypoxia, shifts in vascular diam-
eter and blood–brain barrier disruption injury of the
vascular endothelium–and that this repeated injury is
thought to exhaust the available supply of EPCs [13]. It
has been suggested that endothelial dysfunction is caus-
ally related to migraine (rather than being a consequence
of extensive triptan use or repeated migraine attacks),
as endothelial dysfunction has been demonstrated in
the systemic circulation of individuals with migraine
of recent onset. It may be that the excess EPC in the
SVF aid in the repair of this dysfunction. Similarly,
stem cell depletion at the site of pathology has been
demonstrated in progeria and may also be linked to other
disorders [14].
Other potential mechanisms for the observed decrease
in migraine frequency may be the ability of MSCs to
modulate chronic pain. Guo et al. in 2011 [15] demon-
strated that when neuropathic hyperalgesia was induced
in rats and MSCs were injected both at the site and
IV, they found they were able to produce an analgesic
effect with both modalities although the local injec-
tion effect decreased by 4 weeks and the IV injection
was maintained to the end of the study (4 months).
The use of naloxone at the site initially reversed the
analgesic effect, but was unable to at 4 months. In
contrast, centrally acting naloxone at 4 months was
able to reverse the analgesic effect demonstrating that
MSCs may also act on a central mechanism to down
regulate pain.
While we have observed a treatment that appears to
lead to a relatively effective long-term reduction in mi-
graines and TTH frequency in some patients, we will
continue to monitor the patients to observe the length
of time the patients will remain relatively migraine free be-
fore retreatment is necessary. These original case reports
on the treatment of migraines and TTH by StroMed and
SVF while encouraging requires further trials and proof of
efficacy and understanding of the mechanism of action.
This will require significant input from practitioners who
are experts in the field.
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